Search Results - deug-yong+an

156 Results Sort By:
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors. Key Benefits ST80...
Published: 12/9/2025   |   Inventor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
Keywords(s): Drug Target Identification, Immunotherapy, Oncology Treatments, Small Molecule, Therapeutics
Category(s): TechPub Algolia > Drug Discovery
Gene Editing for Head and Neck Cancer Treatment
Application Method for delivering gene-editing therapeutic in head and neck cancers. Key Benefits CRISPR/CAS9-based gene editing mechanism targeting novel disease-modifying gene. Liquid nanoparticle encapsulation permitting in vivo delivery. Market Summary Head and neck cancers (HNC) are the 7th most common global cancer, accounting for 3%...
Published: 11/7/2025   |   Inventor(s): Yong Teng, Yamin Li
Keywords(s): Drug Discovery, Drug Target Identification, Gene Therapy and Editing, Nanoparticle Drug Delivery, Oncology Treatments, Reagents, Biomaterials, and Plasmids
Category(s): TechPub Algolia > Therapeutics
Combinatorial Therapy for Preserving Muscle Mass During Weight Loss
Application A combinatorial therapy to preserve muscle mass during semaglutide weight loss treatment. Key Benefits Preserves lean mass during semaglutide treatment in preclinical mouse models. Increases overall fat loss without affecting food/water intake during semaglutide treatment in preclinical mouse models. Market Summary The prevalence...
Published: 12/5/2025   |   Inventor(s): Todd Golde, Yong Ran, Eric Krause, Annette De Kloet, Karen Scott
Keywords(s): Antibodies, Biologics, Drug Discovery, Drug Target Identification, Metabolic Disease Treatments, Musculoskeletal Treatments, Personalized Medicine
Category(s): TechPub Algolia > Therapeutics
Parallel Security-Constrained Power System Operation Software
Overview of Technology Fast, flexible, and accurate software tool for multi-period security-constrained power system operation, enhancing decision-making for real-time dispatch, day-ahead market, and weekly scheduling. Background Power grid management faces challenges in ensuring security and efficiency across multiple time periods. Existing solutions...
Published: 10/21/2025   |   Inventor(s): Yong Fu, Fasiha Zainab, Yehong Peng
Keywords(s):  
Category(s): Software
Sensitive Point-of-Care miRNA Detection Using a One-Pot, Isothermal Assay
Rapid, RNA Extraction-Free Detection of miRNAs Biomarkers for Accurate Cancer Diagnosis and Prognosis This CRISPR-Cas12a-based assay allows for the rapid, sensitive detection of microRNAs using a one-pot, isothermal process. MicroRNAs(miRNAs) are endogenous and short, non-coding single-stranded RNAs. They participate in various biological functions...
Published: 5/30/2025   |   Inventor(s): Yong Zeng, He Yan
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Diagnostics, Technology Classifications > Veterinary > Diagnostics
Event-Driven Integrate and Fire (EIF) Neuron Circuit for Neuromorphic Computing System (Case No. 2024-275)
Summary: Researchers in the UCLA Department of Electrical and Computer Engineering have developed an energy efficient neuromorphic computing architecture. Background: Widespread growth in demand for artificial intelligence systems has highlighted limitations in current central processing unit (CPU) designs, particularly in terms of energy efficiency...
Published: 11/18/2025   |   Inventor(s): Mau-Chung Chang, Chao Jen Tien, Yong Hei
Keywords(s): Advanced Computing / AI, advanced computing methods, AI hardware, analog computing, Artifical Intelligence (Machine Learning, Data Mining), artificial electromagnetic materials, Artificial Intelligence, artificial intelligence algorithms, artificial intelligence augmentation, artificial intelligence/machine learning models, artificial intelligence-generated content, Artificial Neural Network, Artificial Neural Network Artificial Neuron, artificial presenting cells, artificial-intelligent materials, Cloud Computing, computational efficiency, computational imaging, compute-in-memory, Computer Aided Learning, Computer Architecture, Computer Monitor, Computer Vision, CPU design, deep neural networks (DNN), Energy Density, Energy Efficiency, event-driven processing, generative artificial intelligence, latency encoding, low latency computing, low-power architecture, matrix multiplication, Medical artificial intelligence (AI), Neuromorphic computing, offline learning, online learning, spike neural networks (SNN), Supercomputer
Category(s): Electrical, Electrical > Signal Processing, Electrical > Electronics & Semiconductors, Electrical > Computing Hardware, Software & Algorithms, Software & Algorithms > Artificial Intelligence & Machine Learning
Treatments for tuberculosis and non-tuberculous mycobacterial infections: dual-targeted rifamycin-AAP conjugates (RifaAAPs)
collapse; } ​ Invention Summary: RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that...
Published: 8/12/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: DUAL-TARGETED RNA POLYMERASE INHIBITORS (BENZOXAZINO-RIFAAAPS
​ Invention Summary: RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that RifaAAPs comprise...
Published: 8/12/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Infectious Disease, Technology Classifications > Healthcare & Life Sciences
ANTIBACTERIAL AGENTS: CO-SOLVENT-FREE, SURFACTANT-FREE FORMULATIONS OF PYRONINS
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 8/12/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: O-ALKYL-DEUTERATED PYRONINS (PYS) AND ARYL PYRONINS (APYS)
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 8/12/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
1 2 3 4 5 6 7 8 9 10 ...